NYSE

Danaher Corporation (DHR)

401 Thanks from members

Danaher Corporation (DHR) demonstrates resilient financial health with expanded EBITDA margins and steady life sciences growth, though sentiment remains tempered by bioprocessing lumpy demand, China revenue headwinds, and Masimo M&A headline risks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →